Introduction
Cardiac Myosin-binding Protein C is a novel biomarker of myocardial ischaemia. Cardiac Troponins T & I have emerged as the gold standard necrosis biomarker for patients presenting with the chest pain and are incorporated into the universal definition of Acute Myocardial Infarction (AMI). A slow release profile means that Troponins reach peak concentrations many hours after symptom onset. The development of high-sensitivity Troponin assays has facilitated the routine detection of ever-smaller concentrations - to allow an earlier triage of patients with chest pain.
What’s the problem?
Nowadays, Troponin concentrations close to the Limit of Detection (LoD) are used as a tool for early rule-out of myocardial infarction. This is at odds with specificity, as chronic or subacute Troponin elevation is common - we frequently detect Troponin values above the LoD in patients with chronic obstructive pulmonary disease (COPD), renal dysfunction and - particularly common - congestive cardiac failure. This has prompted the European Society of Cardiology (ESC) to publish guidance incorporating a 3-tiered risk system for patients presenting with chest pain and no diagnostic ECG changes (bearing in mind this is only validated with onset of chest pain >3 hours ago).
A recent audit at our institution has demonstrated that just over 50% of patients have a Troponin value which falls into the intermediate risk category - an observational ‘grey zone’ with no clear guidance attached. And even the best rule-out and rule-in algorithms rely on repeat measurements 1-3 hours following initial blood draws to optimise sensitivity and specificity, further prolonging hospital stays and psychological burden on patients.
Previous Work
We are actively evaluating cMyC as a novel biomarker of cardiac ischaemia - to improve rule-out ability and to reduce the size of the aforementioned grey zone, and have - thus far - published the following papers:
The discovery paper: cMyC was found in the coronary effluent after myocardial infarction of the isolated, buffer-perfused heart and increased markedly with even trivial infarction.
This is the manuscript using our in-house assay that shows cMyC rises faster than cardiac Troponin T after iatrogenic MI (in patients undergoing alcohol septal ablation) and falls faster after Coronary Artery Bypass surgery.
In this paper we establish the analytic performance of a sensitive assay for cMyC and then its application to ambulatory patients, comparing cMyC with hs-cTnT and hs-cTnI (invasive coronary angiograms showed no significant atherosclerosis). Here we demonstrate that the cMyC assay is very sensitive and cMyC concentration is closely related to hs-cTnT and hs-cTnI and seems perturbed by the same sorts of things (renal dysfunction, age, poor LV function).
This is a brief communication of a highly selected cohort of patients presenting within 3 hours of symptom onset with adjudicated type 1 AMI. Main message is that in these early presenters cMyC is relatively higher than cTnI on presentation and then cTnI catches up.
Stay up to date
…with the latest cMyC developments - email us at info@myosinc.com